SynOx Therapeutics

SynOx is a clinical-stage biopharmaceutical company. SynOx is developing Emactuzumab, a first-in-class CSF1R-targeted therapeutic antibody designed to target and deplete tumor-associated macrophages in tumor tissues. SynOx is led by a team of experts who bring together experience in biotechnology and pharmaceuticals, with a successful track record in product development and commercialization.